Skip to main content

Krystexxa Disease Interactions

There are 2 disease interactions with Krystexxa (pegloticase).

Major

Pegloticase/rasburicase (applies to Krystexxa) G6PD deficiency

Major Potential Hazard, High plausibility. Applicable conditions: G-6-PD Deficiency

The antihyperuricemic agents pegloticase and rasburicase are contraindicated in patients deficient in glucose-6-phosphate-dehydrogenase (G6PD), as these have shown to cause severe hemolytic reactions and methemoglobinemia. Patients at high risk of G6PD deficiency such as patients of African, Mediterranean or Southern Asian ancestry, should be screened prior to starting treatment. Treatment with any of these drugs should be discontinued immediately and permanently in any patient developing hemolysis or methemoglobinemia.

References

  1. (2002) "Product Information. Elitek (rasburicase)." Sanofi Winthrop Pharmaceuticals
  2. (2010) "Product Information. Krystexxa (pegloticase)." Savient Pharmaceuticals
Moderate

Pegloticase (applies to Krystexxa) congestive heart failure

Moderate Potential Hazard, Moderate plausibility.

Pegloticase has not been formally studied in patients with congestive heart failure, and some patients in clinical trials have experienced exacerbation. Caution should be exercised when using pegloticase in these patients and close monitoring following the infusion is recommended.

References

  1. (2010) "Product Information. Krystexxa (pegloticase)." Savient Pharmaceuticals

Krystexxa drug interactions

There are 28 drug interactions with Krystexxa (pegloticase).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer